Neoadjuvant chemo-hormonal therapy improved biochemical progression-free survival in patients with very high-risk prostate cancer, suggesting a new standard of care.
Neoadjuvant chemo-hormonal therapy before robot-assisted radical prostatectomy resulted in favorable biochemical progression-free survival rates in patients with very high-risk prostate cancer. This result suggests that this therapeutic approach has potential for becoming a new standard of care.
No takes yet. Share an insight, caveat, or question.
Koyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: